Comparative Pharmacology
Head-to-head clinical analysis: FASENRA versus ZINBRYTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FASENRA versus ZINBRYTA.
FASENRA vs ZINBRYTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benralizumab is a humanized afucosylated monoclonal antibody that binds to the alpha subunit of the interleukin-5 receptor (IL-5Rα) expressed on eosinophils and basophils. This binding inhibits IL-5-mediated signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in rapid and near-complete depletion of eosinophils from blood and tissues.
Daclizumab is a humanized monoclonal antibody that binds to the alpha subunit (CD25) of the high-affinity interleukin-2 (IL-2) receptor on activated T cells. By blocking IL-2 binding, it inhibits IL-2-mediated activation and proliferation of lymphocytes, which are involved in the pathogenesis of multiple sclerosis.
30 mg subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
150 mg subcutaneously once weekly
None Documented
None Documented
Terminal half-life approximately 25 days (range 24–27 days), supporting every-4-week subcutaneous dosing.
Terminal half-life approximately 21 days (range 18-27 days) following subcutaneous administration, supporting monthly dosing interval.
Degraded into small peptides and amino acids via general protein catabolism; no significant renal or biliary/fecal excretion of intact drug.
Excreted primarily via proteolytic catabolism; not renally or hepatically eliminated. No specific biliary/fecal data available.
Category C
Category C
Monoclonal Antibody, Anti-Interleukin-5 Receptor
Monoclonal Antibody